Resource Center

The American Diabetes Association has updated the Standards of Medical Care in Diabetes. The new standards emphasize patient centered approaches and include new lifestyle management recommendations and a new treatment algorithm for insulin therapy.

This analysis in The Journal of Clinical Endocrinology & Metabolism examines the available resources to manage hypoglycemia and ways to incorporate better management strategies in the clinical setting.

Read this consensus in the American Diabetes Association's Diabetes Care, on the definition of hypoglycemia, including levels of hypoglycemia and the corresponding glycemic criteria.

The Endocrine Society published a strategic blueprint that identifies gaps in knowledge and tools to manage hypoglycemia and provides actionable steps to identify opportunities to reduce the incidence of hypoglycemia.

The National Diabetes Statistics Report is a periodic publication of the Centers for Disease Control and Prevention (CDC) that provides updated statistics about diabetes in the United States for a scientific audience. It includes information on prevalence and incidence of diabetes, pre-diabetes, risk factors for complications, acute and long-term complications, deaths and costs. These data can help focus efforts to prevent and control diabetes across the United States.

A new Agency for Healthcare Research & Quality (AHRQ) systematic review found evidence to support current clinical guidelines identifying metformin as the recommended first-line agent to treat adults with type 2 diabetes. The conclusion is based on the medication's beneficial effects on hemoglobin A1c, weight, cardiovascular mortality (versus sulfonylureas) and relative safety profile. Find the abstract on this report here.

The Food & Drug Administration (FDA) has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, especially in patients with a history or heart or kidney disease. As a result, the FDA is issuing new warnings to the drug labels. These medications include: Onglyza, Kombiglyze XR, Nesina, Kazano and Oseni.

This checklist from the Minnesota Hospital Association/Partnership for Patients is designed for health care facilities to use to conduct a gap analysis of their prescribing, dispensing and monitoring labs for hypoglycemic agents and insulin.

This clinician's guide by the Agency for Healthcare Research and Quality compares the effectiveness and safety of premixed insulin analogues with other insulin preparations and oral diabetes drugs.

Clinician summary released by the Agency for Healthcare Research & Quality on insulin therapy and modes of blood glucose monitoring.

The consumer summary by the Agency for Healthcare Research & Quality reviews research for children, teens, and adults with diabetes, and talks about methods to measure blood sugars and take insulin as well as ways to treat diabetes.

Sensor-augmented insulin pumps (insulin pump combined with real time continuous glucose-blood sugar monitoring) are superior to multiple daily insulin injections and self-monitoring of blood glucose (finger sticks) to reduce high blood sugar in patients with type 1 diabetes, a new review from AHRQ’s Effective Health Care Program has found.

The Agency for Healthcare Research & Quality's Effective Health Care Program featured this report on the use of antidiabetic drugs by Medicare beneficiaries who have diabetes.

This guide provides information on national and local resources for diabetes information.

This reference guide provides information on financial assistance programs for people with diabetes.